All In Biotech

Drug Trial Radar · NCT05121038

CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

A Phase 1B/2A Trial of CEND-1 in Combination with Neoadjuvant FOLFIRINOX Based Therapies in Pancreatic, Colon and Appendiceal Cancers (CENDIFOX)

Last checked: Nov 19, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 20, 2021

Primary completion

Sep 2025

Study completion Sep 2026

Sponsor

Lead sponsor
Anup KasiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cend Therapeutics Inc.
First posted
Nov 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers

Conditions

  • Colon Cancer
  • Pancreas Cancer
  • Digestive Cancer

Interventions

  • CEND-1Drug

    The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).

  • PanitumumabDrug

    Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called "RAS/BRAF wild type" will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX.

  • FolfirinoxDrug

    FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order. All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle). * Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then * Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours. * Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours. then • Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Drug Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Kansas Cancer Center (KUCC)

    Fairway, Kansas

  • The University of Kansas Cancer Center, Westwood Campus

    Kansas City, Kansas

  • The University of Kansas Medical Center

    North Kansas City, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.